Subscribe to our Newsletters !!
Alcohol-based solvents and cleaning agents are pop
Biotech Fluidics offers a range of non-invasive fl
The recent rabies death of an 11 year old Canadian
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micro
The company has received approval from the United States Food and Drug Administration (USFDA) to advertise its own Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement.
The item is a generic version of Biogen Inc”s Tecfidera delayed-release capsules at the same strengths, it added.
The company hopes to launch the product shortly, the announcement said.
According to the IQVIA MAT June 2020 data, Dimethyl Fumarate delayed-release capsules had an annual sales of approximately USD 3,788 million in the US, Lupin said.
The capsules are suggested,”for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and lively secondary progressive disease, in adults,” it added.
PTI AKT RUJ RUJ
